Published in Vaccine Weekly, July 26th, 2006
"It has been calculated that 30-40% of dialysis patients fail to produce antibodies to HBsAg antigen after vaccination towards hepatitis B virus. Several authors have reported on the benefit of thymopentin (TP5) as adjuvant to vaccine against hepatitis B virus in patients receiving regular dialysis.
"However, consistent information on this issue is still lacking," scientists writing in the journal Alimentary Pharmacology & Therapeutics report.
F. Fabrizi and colleagues at IRCCS in Milan conducted a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly